Related Experiment Video

Updated: Jul 14, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis

Mariko Kusaba1, Kazuhiko Nakao, Takashi Goto

  • 1First Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1, Sakamoto, Nagasaki 852-8501, Japan.

Journal of Hepatology
|July 3, 2007
PubMed
Abstract

Insights

AG490, a Janus kinase 2 inhibitor, inhibits STAT3 activation and enhances the anti-tumor effects of TRAIL in human hepatoma cells. This combination therapy repressed tumor growth in mice.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Constitutive activation of Signal transducer and activator of transcription 3 (STAT3) is common in various cancers, regulating cell growth and survival.
  • STAT3 signaling plays a crucial role in the pathogenesis of human hepatoma.

Purpose of the Study:

  • To investigate the anti-tumor effects of AG490, a Janus kinase 2 (JAK2) specific inhibitor, in human hepatoma cells.
  • To evaluate the potential of AG490 in sensitizing hepatoma cells to TRAIL-induced apoptosis.

Main Methods:

  • AG490's effects on STAT3 activation, cell growth, survival, and related protein expression were assessed in multiple hepatoma cell lines (Huh-1, Huh-7, HepG2, Hep3B).
  • In vitro and in vivo studies examined AG490's ability to sensitize hepatoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

Main Results:

  • AG490 effectively inhibited STAT3 tyrosine phosphorylation and activity in all tested hepatoma cells.
  • AG490 induced cell cycle arrest and apoptosis, downregulating key anti-apoptotic proteins (Bcl-xL, survivin, XIAP).
  • AG490 sensitized hepatoma cells to TRAIL-induced apoptosis in vitro, and the combination therapy significantly repressed tumor growth in vivo.

Conclusions:

  • Abrogation of constitutive STAT3 activation by AG490 significantly enhances the anti-tumor efficacy of TRAIL against human hepatoma.
  • Targeting STAT3 with AG490 represents a promising therapeutic strategy for human hepatoma, particularly in combination with TRAIL.

More Related Videos

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...